Demystify Carbapenem-resistant Acinetobacter baumannii Pneumonia Burden: 2-Year Cohort Study
Annals of African Medicine · 2025
DOI: 10.4103/aam.aam_304_24 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of African Medicine, 2025. Verfasst von Alfian Nur Rosyid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology and Respiratory Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Carbapenems, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Introduction
The World Health Organization has identified carbapenem-resistant Acinetobacter baumannii (CRAB) infections as the most important pathogens for which new antibiotics must be developed immediately. Therefore, this study aimed to analyze the comparison of epidemiology, microbial pattern, and antibiotic resistance in CRAB and carbapenem-sensitive A . baumannii (CSAB).
Methods
A retrospective cohort study was used, with community-acquired pneumonia with A . baumannii bacterial culture results. Data were obtained from the patient’s medical record and the results of antibiotic sensitivity testing with the culture method by planting sputum on blood agar and MacConkey medium for 24 h.
Results
A total of 50 patients, CRAB ( n = 26) and CSAB ( n = 24), found that the average gender was male in CRAB compared to CSAB (69.2% vs. 48.2%). Complications of respiratory failure, sepsis, and acute respiratory distress syndrome were higher in CRAB compared to CSAB (30.8% vs. 20.8%, 46.2% vs. 25%, and 2% vs. 0%). The mortality rate in the CRAB group was 53.8% vs. CSAB 12.5%. The mean length of stay (LOS) in CRAB was 17.92, while CSAB was 11.00. The mean cost of hospitalization in CRAB was higher than CSAB ($6993.0615 vs. $3263.7375). The mean neutrophil-to-lymphocyte ratio value in the CRAB group was 20.4, while in CSAB was 10.6.
Conclusions
The results indicated that CRAB infection carries a greater burden in terms of cost of treatment, mortality, LOS, and more serious complications, compared to CSAB infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology and Respiratory Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia.
- Department of Clinical Microbiology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
- Yannas Husada Health Vocational School, Bangkalan, Indonesia.
- Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
- Department of Clinical Pathology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
- Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Zitieren
APA
Rosyid, A. N., Endraswari, P. D., Setiawan, F., Puspitasari, Y., Asmarawati, T. P., Rachman, B. E., Puspitasari, A. D., Sultoni, A. M., & Wulaningrum, P. A. (2025). Demystify Carbapenem-resistant Acinetobacter baumannii Pneumonia Burden: 2-Year Cohort Study. Annals of African Medicine. https://doi.org/10.4103/aam.aam_304_24
Vancouver
Rosyid AN, Endraswari PD, Setiawan F, Puspitasari Y, Asmarawati TP, Rachman BE, et al. Demystify Carbapenem-resistant Acinetobacter baumannii Pneumonia Burden: 2-Year Cohort Study. Annals of African Medicine. 2025. doi:10.4103/aam.aam_304_24
BibTeX
@article{Rosyid2025,
author = {Rosyid, Alfian Nur and Endraswari, Pepy Dwi and Setiawan, Firman and Puspitasari, Yessy and Asmarawati, Tri Pudy and Rachman, Brian Eka and Puspitasari, Arina Dery and Sultoni, Ahmad Mufid and Wulaningrum, Prastuti Asta},
title = {Demystify Carbapenem-resistant Acinetobacter baumannii Pneumonia Burden: 2-Year Cohort Study},
journal = {Annals of African Medicine},
year = {2025},
doi = {10.4103/aam.aam_304_24}
}
EUVIMED